Bronchiolitis Obliterans Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major bronchiolitis obliterans syndrome markets reached a value of US$ 60.5 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 94.0 Million by 2034, exhibiting a growth rate (CAGR) of 4.09% during 2024-2034.
The bronchiolitis obliterans syndrome market has been comprehensively analyzed in IMARC's new report titled "Bronchiolitis Obliterans Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Bronchiolitis obliterans syndrome (BOS) is a progressive lung disease that causes inflammation and scarring of the small airways in the lungs. This scarring, or fibrosis, can cause the airways to become narrow, leading to breathing difficulties and decreased oxygen exchange in the lungs. The primary symptoms associated with this disease include shortness of breath and dry cough. Some individuals may also experience wheezing, fatigue, night sweats, skin rashes, etc. As the disease progresses, the indications may become more severe and can impact daily activities. The diagnosis of BOS is primarily based on clinical symptoms, pulmonary function tests, and imaging studies. Pulmonary function tests, such as spirometry, can assist in determining the severity of the disease by measuring how well the lungs are functioning. Several imaging studies, including chest X-rays or CT scans, can help identify any structural changes in the lungs. Additional tests, such as bronchoscopy and biopsy, may also be performed to aid in confirming the diagnosis and rule out other possible causes of respiratory symptoms.
The increasing incidence of several associated risk factors, such as lung transplantation, respiratory tract infections, connective tissue disorders, exposure to toxins, etc., is primarily driving the bronchiolitis obliterans syndrome market. In addition to this, the escalating usage of effective medications, including bronchodilators, corticosteroids, calcineurin inhibitors, cytotoxic agents, etc., to improve lung function and reduce symptoms of the ailment is augmenting the market growth. Furthermore, the widespread adoption of pulmonary scintigraphy, which utilizes radioisotopes to detect airway and parenchymal abnormalities, for diagnosing the condition is also creating a positive outlook for the market. Besides this, the rising utilization of non-invasive ventilation, which involves providing mechanical support to the lungs via a mask or nasal prongs without the need for invasive procedures like intubation, is further bolstering the market growth. Additionally, numerous key players are making extensive investments in developing new pharmacological agents for treating the ailment, such as drugs that target specific immune pathways. This, in turn, is acting as another significant growth-inducing factor. Furthermore, the emerging popularity of liposomal drug inhalation therapy over traditional systemic drug administration technology owing to its several associated benefits, including increased drug delivery to the lungs and reduced systemic side effects, is expected to drive the bronchiolitis obliterans syndrome market in the coming years.
IMARC Group’s new report provides an exhaustive analysis of the bronchiolitis obliterans syndrome market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for bronchiolitis obliterans syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the bronchiolitis obliterans syndrome market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the bronchiolitis obliterans syndrome market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the bronchiolitis obliterans syndrome market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current bronchiolitis obliterans syndrome marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the bronchiolitis obliterans syndrome market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the bronchiolitis obliterans syndrome market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the bronchiolitis obliterans syndrome market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of bronchiolitis obliterans syndrome across the seven major markets?
What is the number of prevalent cases (2018-2034) of bronchiolitis obliterans syndrome by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of bronchiolitis obliterans syndrome by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with bronchiolitis obliterans syndrome across the seven major markets?
What is the size of the bronchiolitis obliterans syndrome patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of bronchiolitis obliterans syndrome?
What will be the growth rate of patients across the seven major markets?
Bronchiolitis Obliterans Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for bronchiolitis obliterans syndrome drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the bronchiolitis obliterans syndrome market?
What are the key regulatory events related to the bronchiolitis obliterans syndrome market?
What is the structure of clinical trial landscape by status related to the bronchiolitis obliterans syndrome market?
What is the structure of clinical trial landscape by phase related to the bronchiolitis obliterans syndrome market?
What is the structure of clinical trial landscape by route of administration related to the bronchiolitis obliterans syndrome market?
The bronchiolitis obliterans syndrome market has been comprehensively analyzed in IMARC's new report titled "Bronchiolitis Obliterans Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Bronchiolitis obliterans syndrome (BOS) is a progressive lung disease that causes inflammation and scarring of the small airways in the lungs. This scarring, or fibrosis, can cause the airways to become narrow, leading to breathing difficulties and decreased oxygen exchange in the lungs. The primary symptoms associated with this disease include shortness of breath and dry cough. Some individuals may also experience wheezing, fatigue, night sweats, skin rashes, etc. As the disease progresses, the indications may become more severe and can impact daily activities. The diagnosis of BOS is primarily based on clinical symptoms, pulmonary function tests, and imaging studies. Pulmonary function tests, such as spirometry, can assist in determining the severity of the disease by measuring how well the lungs are functioning. Several imaging studies, including chest X-rays or CT scans, can help identify any structural changes in the lungs. Additional tests, such as bronchoscopy and biopsy, may also be performed to aid in confirming the diagnosis and rule out other possible causes of respiratory symptoms.
The increasing incidence of several associated risk factors, such as lung transplantation, respiratory tract infections, connective tissue disorders, exposure to toxins, etc., is primarily driving the bronchiolitis obliterans syndrome market. In addition to this, the escalating usage of effective medications, including bronchodilators, corticosteroids, calcineurin inhibitors, cytotoxic agents, etc., to improve lung function and reduce symptoms of the ailment is augmenting the market growth. Furthermore, the widespread adoption of pulmonary scintigraphy, which utilizes radioisotopes to detect airway and parenchymal abnormalities, for diagnosing the condition is also creating a positive outlook for the market. Besides this, the rising utilization of non-invasive ventilation, which involves providing mechanical support to the lungs via a mask or nasal prongs without the need for invasive procedures like intubation, is further bolstering the market growth. Additionally, numerous key players are making extensive investments in developing new pharmacological agents for treating the ailment, such as drugs that target specific immune pathways. This, in turn, is acting as another significant growth-inducing factor. Furthermore, the emerging popularity of liposomal drug inhalation therapy over traditional systemic drug administration technology owing to its several associated benefits, including increased drug delivery to the lungs and reduced systemic side effects, is expected to drive the bronchiolitis obliterans syndrome market in the coming years.
IMARC Group’s new report provides an exhaustive analysis of the bronchiolitis obliterans syndrome market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for bronchiolitis obliterans syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the bronchiolitis obliterans syndrome market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the bronchiolitis obliterans syndrome market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the bronchiolitis obliterans syndrome market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current bronchiolitis obliterans syndrome marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the bronchiolitis obliterans syndrome market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the bronchiolitis obliterans syndrome market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the bronchiolitis obliterans syndrome market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of bronchiolitis obliterans syndrome across the seven major markets?
What is the number of prevalent cases (2018-2034) of bronchiolitis obliterans syndrome by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of bronchiolitis obliterans syndrome by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with bronchiolitis obliterans syndrome across the seven major markets?
What is the size of the bronchiolitis obliterans syndrome patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of bronchiolitis obliterans syndrome?
What will be the growth rate of patients across the seven major markets?
Bronchiolitis Obliterans Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for bronchiolitis obliterans syndrome drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the bronchiolitis obliterans syndrome market?
What are the key regulatory events related to the bronchiolitis obliterans syndrome market?
What is the structure of clinical trial landscape by status related to the bronchiolitis obliterans syndrome market?
What is the structure of clinical trial landscape by phase related to the bronchiolitis obliterans syndrome market?
What is the structure of clinical trial landscape by route of administration related to the bronchiolitis obliterans syndrome market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 BRONCHIOLITIS OBLITERANS SYNDROME - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 BRONCHIOLITIS OBLITERANS SYNDROME - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 BRONCHIOLITIS OBLITERANS SYNDROME - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 BRONCHIOLITIS OBLITERANS SYNDROME - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 BRONCHIOLITIS OBLITERANS SYNDROME - UNMET NEEDS
10 BRONCHIOLITIS OBLITERANS SYNDROME - KEY ENDPOINTS OF TREATMENT
11 BRONCHIOLITIS OBLITERANS SYNDROME - MARKETED PRODUCTS
11.1 List of Bronchiolitis Obliterans Syndrome Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 BRONCHIOLITIS OBLITERANS SYNDROME - PIPELINE DRUGS
12.1 List of Bronchiolitis Obliterans Syndrome Pipeline Drugs Across the Top 7 Markets
12.1.1 Liposomal Cyclosporine A - zambon spa
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Alvelestat - Mereo BioPharma
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Ruxolitinib - Incyte Corporation/Novartis
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Sirolimus inhaled - AI Therapeutics
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Ciclosporin liposomal - Breath Therapeutics
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. BRONCHIOLITIS OBLITERANS SYNDROME - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. BRONCHIOLITIS OBLITERANS SYNDROME – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 BRONCHIOLITIS OBLITERANS SYNDROME - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Bronchiolitis Obliterans Syndrome - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Bronchiolitis Obliterans Syndrome - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Bronchiolitis Obliterans Syndrome - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Bronchiolitis Obliterans Syndrome - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Bronchiolitis Obliterans Syndrome - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Bronchiolitis Obliterans Syndrome - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Bronchiolitis Obliterans Syndrome - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Bronchiolitis Obliterans Syndrome - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Bronchiolitis Obliterans Syndrome - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Bronchiolitis Obliterans Syndrome - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Bronchiolitis Obliterans Syndrome - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Bronchiolitis Obliterans Syndrome - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Bronchiolitis Obliterans Syndrome - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Bronchiolitis Obliterans Syndrome - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Bronchiolitis Obliterans Syndrome - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Bronchiolitis Obliterans Syndrome - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Bronchiolitis Obliterans Syndrome - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Bronchiolitis Obliterans Syndrome - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Bronchiolitis Obliterans Syndrome - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Bronchiolitis Obliterans Syndrome - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Bronchiolitis Obliterans Syndrome - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Bronchiolitis Obliterans Syndrome - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Bronchiolitis Obliterans Syndrome - Access and Reimbursement Overview
16 BRONCHIOLITIS OBLITERANS SYNDROME - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 BRONCHIOLITIS OBLITERANS SYNDROME MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 BRONCHIOLITIS OBLITERANS SYNDROME MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 BRONCHIOLITIS OBLITERANS SYNDROME - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 BRONCHIOLITIS OBLITERANS SYNDROME - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 BRONCHIOLITIS OBLITERANS SYNDROME - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 BRONCHIOLITIS OBLITERANS SYNDROME - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 BRONCHIOLITIS OBLITERANS SYNDROME - UNMET NEEDS
10 BRONCHIOLITIS OBLITERANS SYNDROME - KEY ENDPOINTS OF TREATMENT
11 BRONCHIOLITIS OBLITERANS SYNDROME - MARKETED PRODUCTS
11.1 List of Bronchiolitis Obliterans Syndrome Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 BRONCHIOLITIS OBLITERANS SYNDROME - PIPELINE DRUGS
12.1 List of Bronchiolitis Obliterans Syndrome Pipeline Drugs Across the Top 7 Markets
12.1.1 Liposomal Cyclosporine A - zambon spa
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Alvelestat - Mereo BioPharma
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Ruxolitinib - Incyte Corporation/Novartis
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Sirolimus inhaled - AI Therapeutics
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Ciclosporin liposomal - Breath Therapeutics
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. BRONCHIOLITIS OBLITERANS SYNDROME - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. BRONCHIOLITIS OBLITERANS SYNDROME – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 BRONCHIOLITIS OBLITERANS SYNDROME - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Bronchiolitis Obliterans Syndrome - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Bronchiolitis Obliterans Syndrome - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Bronchiolitis Obliterans Syndrome - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Bronchiolitis Obliterans Syndrome - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Bronchiolitis Obliterans Syndrome - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Bronchiolitis Obliterans Syndrome - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Bronchiolitis Obliterans Syndrome - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Bronchiolitis Obliterans Syndrome - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Bronchiolitis Obliterans Syndrome - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Bronchiolitis Obliterans Syndrome - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Bronchiolitis Obliterans Syndrome - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Bronchiolitis Obliterans Syndrome - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Bronchiolitis Obliterans Syndrome - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Bronchiolitis Obliterans Syndrome - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Bronchiolitis Obliterans Syndrome - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Bronchiolitis Obliterans Syndrome - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Bronchiolitis Obliterans Syndrome - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Bronchiolitis Obliterans Syndrome - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Bronchiolitis Obliterans Syndrome - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Bronchiolitis Obliterans Syndrome - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Bronchiolitis Obliterans Syndrome - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Bronchiolitis Obliterans Syndrome - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Bronchiolitis Obliterans Syndrome - Access and Reimbursement Overview
16 BRONCHIOLITIS OBLITERANS SYNDROME - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 BRONCHIOLITIS OBLITERANS SYNDROME MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 BRONCHIOLITIS OBLITERANS SYNDROME MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
